Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66.
Nieder
Carsten
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001254:Astrocytoma / Q000378:metabolism / Q000532:radiotherapy; D001927:Brain Diseases / Q000209:etiology*; D001932:Brain Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D016190:Carboplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D016228:Endothelial Growth Factors / Q000378:metabolism*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D008130:Lomustine / Q000008:administration & dosage; D008222:Lymphokines / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D009837:Oligodendroglioma / Q000378:metabolism / Q000532:radiotherapy; D011832:Radiation Injuries / Q000209:etiology*; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D009363:Neoplasm Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008130:Lomustine; D016190:Carboplatin; D017479:Receptors, Platelet-Derived Growth Factor